• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    5/8/24 12:31:09 PM ET
    $CLOV
    $DH
    $ELAN
    $GMED
    Medical Specialities
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $CLOV alert in real time by email

    Gainers

    • MaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday.
    • Elanco Animal Health (NYSE:ELAN) stock moved upwards by 25.25% to $16.93. The market value of their outstanding shares is at $8.3 billion. The company's, Q1 earnings came out today.
    • Globus Medical (NYSE:GMED) shares rose 22.17% to $62.75. The company's market cap stands at $8.4 billion. The company's, Q1 earnings came out yesterday.
    • Clover Health Investments (NASDAQ:CLOV) stock moved upwards by 20.63% to $0.89. The company's market cap stands at $442.6 million. As per the press release, Q1 earnings came out yesterday.
    • Vigil Neuroscience (NASDAQ:VIGL) stock moved upwards by 17.86% to $3.76. The company's market cap stands at $141.3 million. As per the press release, Q1 earnings came out yesterday.
    • Syra Health (NASDAQ:SYRA) stock rose 17.35% to $1.76. The company's market cap stands at $11.6 million.

    Losers

    • Treace Medical Concepts (NASDAQ:TMCI) shares fell 62.3% to $4.19 during Wednesday's regular session. The company's market cap stands at $259.5 million. The company's, Q1 earnings came out yesterday.
    • Inspire Medical Systems (NYSE:INSP) shares decreased by 34.69% to $160.44. The market value of their outstanding shares is at $4.8 billion. The company's, Q1 earnings came out yesterday.
    • Definitive Healthcare (NASDAQ:DH) shares declined by 31.52% to $4.96. The company's market cap stands at $584.8 million. The company's, Q1 earnings came out yesterday.
    • Seres Therapeutics (NASDAQ:MCRB) stock declined by 30.64% to $0.77. The company's market cap stands at $116.2 million. As per the news, the Q1 earnings report came out today.
    • SIGA Technologies (NASDAQ:SIGA) shares fell 22.47% to $8.11. The market value of their outstanding shares is at $576.7 million. As per the press release, Q1 earnings came out yesterday.
    • Semler Scientific (NASDAQ:SMLR) stock fell 21.25% to $22.17. The market value of their outstanding shares is at $155.8 million. The company's, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CLOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV
    $DH
    $ELAN
    $GMED

    CompanyDatePrice TargetRatingAnalyst
    Inspire Medical Systems Inc.
    $INSP
    2/13/2026Outperform → Peer Perform
    Wolfe Research
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$74.00Outperform → Neutral
    Robert W. Baird
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$70.00Overweight → Equal Weight
    Wells Fargo
    Globus Medical Inc.
    $GMED
    1/30/2026$112.00Hold → Buy
    Needham
    Globus Medical Inc.
    $GMED
    1/27/2026$110.00Buy
    TD Cowen
    Inspire Medical Systems Inc.
    $INSP
    1/27/2026$90.00Outperform → Sector Perform
    RBC Capital Mkts
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026$96.00Buy → Hold
    Truist
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026Outperform → Perform
    Oppenheimer
    More analyst ratings

    $CLOV
    $DH
    $ELAN
    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by Wolfe Research

    Wolfe Research downgraded Inspire Medical Systems from Outperform to Peer Perform

    2/13/26 8:29:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Inspire Medical Systems from Outperform to Neutral and set a new price target of $74.00

    2/12/26 7:22:54 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Inspire Medical Systems from Overweight to Equal Weight and set a new price target of $70.00

    2/12/26 7:22:44 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit ("RSU") award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte. The awards were granted unde

    3/31/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac

    3/27/26 10:15:00 AM ET
    $CLOV
    $LIVN
    $MBOT
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Biological Products (No Diagnostic Substances)

    $CLOV
    $DH
    $ELAN
    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Masoud Maher

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    3/31/26 4:12:11 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Miller Larry R.

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    3/26/26 6:07:59 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:43:49 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    SEC Filings

    View All

    Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    4/1/26 8:32:45 AM ET
    $CLOV
    Medical Specialities
    Health Care

    MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MAXCYTE, INC. (0001287098) (Filer)

    3/27/26 4:54:45 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.

    SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject)

    3/27/26 10:34:15 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

    SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    11/14/24 4:19:18 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

    ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in

    3/23/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026  Seres operational focus on advancing live biotherapeutic programs for inflammatory and immune diseases Company working to create meaningful partnerships with collaborators to support continued development of pipeline programs, including SER-155 for allogeneic hematopoietic stem cell transplant (allo-HSCT)  CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fou

    3/12/26 7:00:00 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLOV
    $DH
    $ELAN
    $GMED
    Financials

    Live finance-specific insights

    View All

    SIGA Declares Special Cash Dividend of $0.60 Per Share

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. The amount of this dividend is consistent with the level of the special dividend declared in April 2025. The dividend is payable on April 23, 2026, to shareholders of record at the close of business on April 7, 2026. "Today's announcement of a special cash dividend reflects the strength of our balance sheet and focus on maximizing shareholder value," said Diem Nguyen, Chief Executive Officer. "We remain committed to executing our st

    3/26/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

    Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform

    3/24/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update

    Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026  Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. "In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income," stated Diem

    3/10/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care